Nerve growth factor inhibitor with novel‐binding domain demonstrates nanomolar efficacy in both cell‐based and cell‐free assay systems

Authors:

Abstract
Nerve growth factor (NGF), a member of the neurotrophin family, is known to regulate the development and survival of a select population of neurons through the binding and activation of the TrkA receptor. Elevated levels ofNGFhave been associated with painful pathologies such as diabetic neuropathy and fibromyalgia. However, completely inhibiting theNGFsignal could hold significant side effects, such as those observed in a genetic condition called congenital insensitivity to pain and anhidrosis (CIPA). Previous methods of screening forNGF‐inhibitors used labeling techniques which have the potential to alter molecular interactions.SPRspectroscopy andNGF‐dependent cellular assays were utilized to identify a novelNGF‐inhibitor,BVNP‐0197 (IC50 = 90 nmol/L), the firstNGF‐inhibitor described with a high nanomolarNGFinhibition efficiency. The present study utilizes molecular modeling flexible docking to identify a novel binding domain in the loopII/IVcleft ofNGF.

This publication has 43 references indexed in Scilit: